Continuous infusion of 5-fluorouracil with versus without low-dose, consecutive administration of cisplatin in advanced colorectal cancer. A prospective randomized phase II study

Journal of Experimental and Clinical Cancer Research

Volumn 26, Issue 1, 2007, Pages 51-60

  Nakata, Bunzo ^a   Sowa, M ^a   Tsuji, A ^b   Kamano, T ^c   Sasaki, K ^d   Fukunaga, Y ^e   Takahashi, M ^f   Tsujitani, S ^g   Mikami, Y ^h   Mitachi, Y ⁱ   Nishimura, S ^j   Araki, H ^k   Yamamitsu, S ^l   Hirakawa, K ^a   Tominaga, S ^m   Shirasaka, T ⁿ   Inokuchi, K ^o  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b National Hospital Organization   (Japan)

^c JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d Doto Hospital   (Japan)

^e OSAKA CITY GENERAL HOSPITAL   (Japan)

^f Asahikawa Kosei Hospital   (Japan)

^g TOTTORI UNIVERSITY   (Japan)

^h AOMORI PREFECTURAL CENTRAL HOSPITAL   (Japan)

ⁱ Sendai Kosei Hospital   (Japan)

^j SUMITOMO HOSPITAL   (Japan)

^k Fujimoto Hospital Medicine   (Japan)

^l Sapporo Tsukisamu Hospital   (Japan)

^m Aichi Health Promotion Foundation   (Japan)

ⁿ KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^o Japanese Foundation for Multidisciplinary Treatment of Cancer   (Japan)

more..

Author keywords

5 fluorouracil; Colorectal cancer; Low dose cisplatin

Indexed keywords

CISPLATIN; FLUOROURACIL;

ADD ON THERAPY; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER LOCALIZATION; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ECZEMA; FATIGUE; FEMALE; HAND FOOT SYNDROME; HEART ARRHYTHMIA; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; JAPAN; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PROSPECTIVE STUDIES; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 34247476030     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Lokich J.J., Ahlgren J.D., Gullo J.J., et al: A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J. Clin. Oncol. 7:425-432, 1989.
2. Hansen R.M., Ryan L., Anderson T., et al: Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer. J. Natl. Cancer Inst. 88:668-674, 1996.
3. The Meta-analysis Group in Cancer: Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J. Clin. Oncol. 16:301-308, 1998.
4. Kondo K., Murase M., Kodera Y., et al: Feasibility study on protracted infusional 5-fluorouracil and consecutive low-dose cisplatin for advanced gastric cancer. Oncology 53:64-67, 1996.
5. Chung Y.S., Yamashita Y., Inoue T., et al: Continuous infusion of 5-fluorouracil and low dose cisplatin infusion for the treatment of advanced and recurrent gastric adenocarcinoma. Cancer 80:1-7, 1997.
6. Kim R., Murakami S., Ohi Y., et al: Aphase II trial of low dose administration of 5-fluorouracil and cisplatin in patients with advanced and recurrent gastric cancer. Int. J. Oncol. 15:921-926, 1999.
7. Scanlon K.J., Newman E.M., Lu Y., et al: Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. P. Natl. Acad. Sci. USA 83:8923-8925, 1986.
8. Shirasaka T., Shimamoto Y., Ohshimo H., et al: Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo. Cancer Chemoth. Pharm. 32:167-172, 1993.
9. Araki H., Fukushima M., Kamiyama Y., et al: Effect of consecutive lower-dose cisplatin in enhancement of 5-fluorouracil cytotoxicity in experimental tumor cells in vivo. Cancer Lett. 160:185-191, 2000.
10. Kurihara M., Shimizu H., Tsuboi K., et al: Development of quality of life questionnaire in Japan: quality of life assessment of cancer patients receiving chemotherapy. Psycho-Oncol. 8:355-363, 1999.
11. de Gramont A., Figer A., Seymour M., et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol. 18:2938-2947, 2000.
12. Saltz L.B., Cox J.V., Blanke C., et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. New Engl. J. Med. 343:905-914, 2000.
13. Tournigand C., Andre T., Achille E., et al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J. Clin. Oncol. 22:229-237, 2004.
14. Rothenberg M.L., Meropol N.J., Poplin E.A., et al: Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J. Clin. Oncol. 19:3801-3807, 2001.
15. Kemeny N., Israel K., Niedzwiecki D., et al: Randomized study of continuous infusion fluorouracil versus fluorouracil plus cisplatin in patients with metastatic colorectal cancer. J. Clin. Oncol. 8:313-318, 1990.
16. Lokich J.J., Ahlgren J.D., Cantrell J., et al: A prospective randomized comparison of protracted infusional 5-fluorouracil with or without weekly bolus cisplatin in metastatic colorectal carcinoma. A Mid-Atlantic Oncology Program study. Cancer 67:14-19, 1991.
17. Nakata B., Mitachi Y., Tsuji A., et al: Combination phase I trial of a novel oral fluorouracil derivative S-1 with low-dose cisplatin for unresectable and recurrent gastric cancer (JFMC-27-9902). Clin. Cancer Res. 10:1664-1669, 2004.
18. Yagihashi A., Sasaki K., Hirata K., et al.: Study of serum CDDP concentrations in patients with advanced or recurrent adeno-or squamous cell carcinoma under combination chemotherapy of 5-FU (CIV) and low-dose CDDP (IV). Gan to Kagaku Ryoho (Jpn. J. Cancer Chemother.) 23:63-67, 1996.